Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
作者:Jinhong Bai、Chenzhong Liao、Yanghan Liu、Xiaochu Qin、Jiaxuan Chen、Yatao Qiu、Dongguang Qin、Zheng Li、Zheng-Chao Tu、Sheng Jiang
DOI:10.1021/acs.jmedchem.6b00324
日期:2016.6.23
a new class of potent small-molecule inhibitors of NAMPT. Several designed compounds showed promising antiproliferative activities in vitro. (E)-N-(5-((4-(((2-(1H-Indol-3-yl)ethyl)(isopropyl)amino)methyl)phenyl)amino)pentyl)-3-(pyridin-3-yl)acrylamide, 30, bearing an indole moiety, has an IC50 of 25.3 nM for binding to the NAMPT protein and demonstrated promising inhibitory activities in the nanomolar
烟酰胺磷酸核糖基转移酶(NAMPT)的抑制作用有可能直接限制癌细胞中NAD的产生,是治疗癌症的有效策略。使用基于结构的策略,我们设计了一类新型的NAMPT强效小分子抑制剂。几种设计的化合物在体外显示出有希望的抗增殖活性。(E)-N-(5-((4-((((2-(1 H-吲哚-3-基)乙基)(异丙基氨基)甲基)苯基)氨基)戊基)-3-(吡啶基-3带有吲哚部分的30-基)丙烯酰胺的IC 50为25.3 nM,可与NAMPT蛋白结合,并且在纳摩尔范围内表现出对几种癌细胞系的有希望的抑制活性(MCF-7 GI 50= 0.13 nM;MDA-MB-231 GI 50 = 0.15 nM)。三阴性乳腺癌是最恶性的乳腺癌亚型,目前尚无有效的靶向治疗方法。在原位MDA-MB-231三阴性乳腺癌异种移植肿瘤模型中,实现了化合物30的显着抗肿瘤功效(TGI为73.8%)。本文报道了有希望的抑制NAMPT的先导分子,可作为进一步研究的基础。